[illegible]

[illegible].

[illegible]— [illegible]

[illegible]

⚠ [illegible]

[illegible]

[illegible]: **findahelpline.com** '[illegible]: **112** '[illegible], [illegible] **(GABRB3-**[illegible]**) GABA** [illegible]—[illegible] [illegible]

[illegible] (Drugs.com, Medscape) [illegible]

□□ □□□□ □□ □□□□□ □□□□□ □□□□ □□

□□□□ □□□□□□□□□ □□ □□□ □□□□ □□□□□□ □□ □□ □□□□□ □□□ □□□□ □□ □□□□ □□□□ □□□□□□ □□ □□□□□ □□: □□□□ □□□□□ □□ □□□ □□□□□ □□ □□ □□□□ □□□ □□ □□□□□□□□□□□□ □□□ □□□□□ □□□□ □□□□□□□ □□□□□ □□, □□□ □□□□□□ □□□ □□□□□ (DNA) □□□ □□□□□□ □□□ □□□□ □□ □□□□ □□ □□□□□ □□□□□□□ □□ □□□□ □□? □□ □□□□□□□□ □□ □□□□ □□□ □□□□□ □□, □□ □□ □□□ □□□□□ □□□ □□□□ □□□□ □□ □□□ □□□□□ □□□□□ □□□□□□□ □□□□ □□□□ □□□

- □□□□□ □□□ — □□□□ □□□□□□ □□□□ □□□□ □□□□□ □□ □□□□□□□□□□ → □□□ **VCF** □□□□ → □□□□□ □□□□□□□□□□ □□□□ □□□□□ □□□ □□□ □□□□□□□ □□□□ □□ □□□□, □□□ □□□□□ □□□□□□□□ □□□-□□□□□□□□ □□ □□ □□□ □□ □□□□ □□□
- □□□ **2** — □□ □□□ □□□□□□□□□ □□□ □□□□□: **MTHFR (□□□□□)**, **COMT (□□□□)**, **CYP2D6 (□□□□□□□□□□)**, **GABRA2/GABRB3** □□□□□□□□ □□□□□ (□□□□□□□ □□□□□□), □□□ **OPRM1/DRD2** □□□□□□ □□□□□ □□□□ □□□□ □□□ □□□□□□□ □□□□□ □□, □□□ □□□□ □□□□□ □□□□□□ □□□□□□□□□ □□□ □□□□□ □□□
- □□□ **3** — □□□□ □□□□□□ □□□□□□□□ □□□ □□□□□□□ □□ □□□□□ □□□ □□□□ □□□ □□□□□□□ □□□□ □□□ □□□□ □□ □□□□ □□□□ □□ □□□ □□□□□ □□□□ □□□□□□□ □□ □□□ □□□□□ □□ □□ □□□□□□□□ □□ □□□□ □□□□ □□ □□□
- □□□□ □□□ — □□□□□□□□□□□□ □□□□□ □□□□ □□□□ □□□□□□□□ □□□□□□ **(stimulant)**, □□□□□□□□□ **(dissociative)** □□□ □□□□□ **(opioid)** □□□□ □□□-□□□ □□□□□ □□□ □□□□□ □□ □□□□ □□□ □□□□ □□□□□□□□: □□□□□, □□□□□□□□, □□□□□□.
- □□□ **5** — □□□□, □□□□ □□□ □□□□ □□□□□ □□□□—□□ □□□□ □□□□ □□□ □□□□ □□□□□ □□ □□□□□□□ □□□□-□□□□ □□ □□□□□□□ □□□□□ □□, □□□ □□ □□□□□□ □□□□ □□ □□□□□□□ □□□□ □□□□ □□□□ □□□
- □□□□□ □□□ □□□□, □□ □□□ □□ □□□□□□ □□□ □□□□ □□□□ □□ □□□□□ □□□□ □□□ □□□□□□ □□□□□ □□□□□ □□ □□□□□ □□□ □□□ **AI** □□□□□□□□ □□□□ □□□□ □□ □□□□□□□ □□□□□□□ □□□ □□□□□□ □□□□ □□□

□□□□ □□□ □□□□ □□ □□□□□ □□□□□ □□ □□□□ □□□ □□□□□ □□□□ □□□

□□□□□□ □□□□□□□□ (□□□ □□□□□□), □□□ □□□□□□ □□□□□□ □□□□ □□□□□□, □□□ □□□ □□□□ □□□□□□ □□□□ □□□□□□ □□ □□□□□□□□ □□□□ □□□□□□□ □□□□□□□□□□□ (□□□□□□ □□□□□□) □□□□ □□□ □□□ □□□□□□ □□□□ □□□□□□ □□—□□□ □□□□-□□□ □□□□ □□□ □□—□□□□ □□□□ □□□□ □□□ □□□□□ □□□□ □□□ □□□ □□□ □□□□, □□□□ □□ □□ □□□□ □□□□ □□□□ □□□□□□ □□□ '□□ □□ □□□ □□, □□□□ □□□ □□□□ □□□ □□□□□, □□□ □□ □□□□□□ (□□□ □□□□ □□□) □□ □□□□ □□ □□□□ □□, □□ □□□□ □□□□□ □□ □□□ □□□□ □□□□□□

□□□□□ □□□ - □□□□ □□□□□□ □□□□

1a. □□□□□ □□□□□: □□□□□□□□□□ → VCF → □□□□□□□□□□

□□ □□□□□□□ □□□ □□□□□□ □□ □□□□ '□□ □□□□ □□□□ □□□ □□: □□□ □□□□ □□□□□ □□ □□□□□□□ □□□ VCF □□□□ □□□□□□□ □□, □□□ □□□□□□□□□ □□ □□□□ □□□ □□□□□□ □□ □□□ □□□□□ □□□□□ □□ □□□□□□□ □□□□□ □□, □□□ □□□ □□□□□□□□ □□ □□□□□ □□□ □□□□□□ □□□ □□□ □□□□ □□□□ □□□□ □□□□□ □□□ □□ □□□□ □□□□□□□□ □□:

Test.	□□ □□□□□□□ □□ □□□□□ □□□	□□□□□□□ □□□□ □□□□□□□
30 □□□ □□□□ □□□□□ □□ □□□□□□□□□□ (Nebula, Dante, Sequencing.com)□	□□□□ □□□□□; □□□ VCF □□□□— □□ □□ □□□□ □□□□ □□ □□□□□ □□□□□□□□□ □□□ □□□ □□□□□ □□□ □□□□ $200–400, □□□ □□□□	□□□□□□□□ □□□□ □□ □□□□□□□□□ VCF □□□ □□□□□ □□□□ □□ □□ □□□ □□□ □□ □□□□ □□ □□□ □□□ □□□□ □□□□□— □□□□□ □□□□ □□□□□ □□□□□□□□ □□□□ □□□□□
□□□□□□□ SNP □□□ (23andMe, Ancestry)	□□□□ 700 □□□□□ □□□□□□ □□□ □□□□ □□ SNP (□□□□□ □□□□□□□□□□ □□□□□□□□□□□) □□□ .txt □□□□ □□□□; □□ MTHFR, COMT, DRD2, □□□ □□□ CYP □□□ □□□ □□□□ □□□	□□ □□□ □□□□ □□□□□□ □□□ □□ VCF □□□□ □□□□ □□□□□□□, □□ □□ □□□ □□□□□ □□□□□ □□ □□□□ □□□ □□□□□ Genetic Genie (□□□□) □□□ Promethease (~$12) '□□ □□□□□□ □□□□
□□□□□□□ □□□□□□□□□□□□□□ □□□□ (GeneSight, Mayo GeneGuide).	□□□□□□□-□□□□□ CYP2D6/2C19/3A4 □□□□, □□ □□□□□ □□ □□□□□ '□□ □□□□ □□□□□ □□□	□□ □□□□/ □□□□□ □□□□□ □□□□ □□□ □□ □□□ □□□□□□□□□ □□□□ □□□□□□□□□ □□; □□ □□□□ □□□□□□□□ □□ WGS □□ □□□□□ □□□□ □□□□□
□□□ □□□□ □□□□□□□□□□ □□ □□□□□□ (□□□□□□□□□□, □□12, □□□□□□ □□□□□)□	□□□□□□□ □□□□□□□□□, □□ □□ □□□□□□□□ □□□□□ □□□□□ □□□□ □□□□□□ □□ □□□□□ □□□ □□□□□□□ □□ □□□□□ □□□□	□□□□□ □□□□□□□□ □□□□□□□□□□ □□ □□□ □□□□□□□□ □□□ □□□□□□□□□ □□□□□

□□□□□□□□□ **+** □□□□□□□□: **VCF** □□□□□ □□□□□□□□□ □□□□□ □□□□□ □□, □□ □□□□ **16** □□□□□ □□□□□ **(**□□□□□□□□□□□□□, □□□-□□□□□□□, □□□□□-□□□□, □□□□□□□□□□□□, □□□□□-□□□□□□□□□□□□□, □□□**)** □□ □□□□□□□ □□□□ □□□ □□ □□□ □□□□□□□□ □□□□ □□□□□ □□, □□ □□□□□□ □□□□ □□ □□□□ □□ □□□□□□□□□□ □□ □□□ □□□□□ □□□ □□□□□□□□□ □□□ □□□□□ □□□□ □□□□□ □□: □□ □□□□□□□ □□□ □□□□ □□□ **-** □□□ □□□□□ □□ □□□□□□□ □□□ □□ **-** □□□□ □□□□□ □□□ □□□□□□ □□□□□ □□ □□□□

□□□□ □□□□□□□ □□□**:** □□□□ □□□□□□□ □□□ □□ □□□□ □□□□□ □□□ □□□□ □□ □□ □□□□□ '□□ □□□ □□□□□□ □□**,** □□□ □□□□ □□□ □□□ □□□□□□ □□□□□ □□□ □□□□□□□□□□□□□□ □□□□ □□□□□□ □□ □□□□ **CYP2D6** □□ □□□□□ □□□ **FDA** □□ **60** □□□ □□□ □□□□□□ □□□ □□□□□ □□□□□ □□—□□ □□□ □□□□□□□ □□□ □□□□ □□□□□□ □□□□□□□□□ □□□□□□□□□ □□**,** □□□ □□□□□ □□□ □□□□ □□ □□□□□ □□□□□□ □□□ □□□□□□ □□□□□ □□□ □□□□ □□□□□□ □□□ □□ □□□ □□□ □□□

□□ □□□□□ □□□ □□□ □□□□ □□□□ □□ □□□□: □□□□□ □□□□□□□□ □□□□□□□

□□ □□□ □□□□□ □□□□□ □□ □□□ □□□□□□□□ □□□-□□□□□□□□ □□□□□ □□ (□□□□ 1 □□ □□□□□ 2/3 □□□□ □□□□□□□□□□, □□□□□□□□□□ □□ □□□□□□□□□ 06, □□□ GABA □□□□□ □□□□ □□□□□□□□-□□□□□ □□ □□□□□□□□)□ □□ □□□□□□□□□ □□□□□□□— □□□□□□□ □□□□□□, □□□□□□ □□ □□□□□□□□, □□□□□□□□□ □□□ □□□□□ □□ □□□□□—□□ □□□□□ □□□□ □□ □□□ □□ □□□□ 15 □□□□ □□□□ □□□□□□ □□ □□□ □□□□□□□□ □□□□□ □□□□ □□□□ □□ □□□, □□ □□□□□□ □□□□□ □□□ □□ □□□□□□□ □□□□□ □□□□ □□□ □□□□ 60-80% □□□ □□ □□□□□ □□; □□□□□ □□□ □□□□□ □□□□ □□□ □□□□ □□□□□ □□□□□□□ □□□ □□□ □□□□□ □□□□□ □□□□ □□ □□□ □□□□□□□□ □□□□□ □□, □□□ □□□□ □□□□□ □□□□— □□ □□ □□□□□□□□ □□□ □□□ □□□□□ □□□ □□ □□□□□ □□□

□□□ 2 — □□ □□□ □□□□□□□□□ □□□□ □□□□□□

□□□ □□□□□ □□□ □□□□□□□□ □□; □□□□□□ □□□ □□□ □□□□ □□□□ □□□□□, □□ □□□□□ □□ □□□□□ □□ □□ □□□□ □□, □□□ □□□□ □□□□□ □□□ □□□□ □□□ □□□□□ □□□

□□□□□ 1 — MTHFR (□□□□□ □□□□)□

□□ □□ □□□□□□□ □□□□ □□ □□ □□□□□ □□□□□ □□□ □□□□□ □□□□□ □□□ □□ □□□□□ □□□ □□□□ □□□□□ □□ □□□□□ □□□□□ □□□□□ □□□□□□□□□□□□□□ □□□□□ □□ □□□□□ □□□ □□□ □□□□ □□□□ □□□□ □□□□□□ □□□□□□□□ □□□ □□□ □□ □□□□ □□□ MTHFR □□ □□□□□□ □□ □□□□□□ □□□□ □□□□ □□□□□ □□ - □□ □□□□ □□ □□□ □□□□-□□□ □□□□ □□□□□ □□□ □□□□□□ □□□□□□ □□□ □□□ □□□□ □□, □□□ □□□□ 40% □□□□□ □□□□ □□□□ □□□□□□□□□□□ □□□ □□□□□ □□□

□□□□ □□□□, □□□ □□□□□□ □□□□□ □□□ □□□ □□□□ □□□□□ □□□□□ □□□□ □□□□ □□□□□ □□□ □□□□□ □□□□□	□□□□	□□ □□ □□□□□ □□□
C/C (□□□□ □□□□)	□□□□ 100% □□□□□□□□□	□□ □□□ '□□, □□□□□□□□□□ □□□□□□□□□ □□ □□□ □□□□ □□□□□; □□□□□ □□□□-□□□□□□□ □□ □□□□□ □□□
C/T (□□□□□□□□□□□□)	□□□□ 60-65% □□□□□□□□□	□□□□□□□□□□ □□□□□□ □□□ □□□ □□ □□□□ □□, □□□ □□□□ □□□□ □□ □□□□□
T/T (□□□□□□□□□□)	□□□□ 30-40% □□□□□□□; □□□ □□□□ □□□□□□□	□□□□□□□□□□ □□□□□□□□□ □□□□ □□□□□□ □□—□□ □□□ □□□□ □□, □□□ □□□□ □□□□ □□□□□
□□□□□□□ □□□ (C/T + A1298C A/C)	□□□□□□ □□□□ □□; □□ T/T □□□□ □□□ □□□□ □□□	□□□□□ □□□□□ □□ □□□□□ □□□□ □□□□ □□□□□ □□□ □□□ □□□□ * Recovery Kernel * Naloxone * COMT * DRD2 * MTHFR * Blueprint * findahelpline.com

MTHFR □□□□ □□□ □□□□□□ □□□□□

□□□□ □□ **T** □□□□ □□□□ □□□□□□□□ □□□ □□□□□□□□ □□□□□ □□□□ **(**□□□□□□□□□ □□□□ □□□ □□□□ □□□□□□□□□□□□□ □□□□**)** □□□ □□□ □□ □□□ □□□ □□□ □□□□ □□□□ □□□□□□□ □□□□□ □□□□ □□□ □□□□; □□ □□□ □□□□□ □□ □□□ □□ □□□□□ □□□ □□□ □□□□□ □□ □□ □□□□ □□□□□ □□□ □□□□□□□□ □□□□□□ □□□□□□□□ □□, □□□□□□□□ □□ □□□□□ □□□ □□□ □□□□ □□ □□□□□ □□□ □□□□ □□□□ □□□ □□□□ □□□ □□□□□□ □□□□□□□□□□ **/** □□□-□□□□□□□□□□ **/ 5-MTHF /** □□□□□□□□□□□ □□ □□□□□

[illegible]	[illegible]	[illegible]
[illegible]		

[illegible] 2 - COMT ([illegible] [illegible] [illegible]: [illegible] [illegible] [illegible]/[illegible] [illegible] [illegible])

[illegible] [illegible] [illegible] [

[illegible], [illegible]	[illegible]	[illegible]
(PM).	[illegible] [illegible]/[illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
[illegible] (IM)	[illegible] [illegible] [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
[illegible] (NM)	[illegible] [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible]
[illegible] (UM)	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] 4 — GABRA2 / GABRB3 ([illegible])[illegible]

[illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] GABRA2 [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] '[illegible]' [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible], [illegible] [illegible]	[illegible]	[illegible] [illegible] [illegible]
GABRA2 [illegible] [illegible] (rs279858 T-[illegible]) — [illegible] 15–20%	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible]	[illegible]/[illegible] [illegible] '[illegible] [illegible] [illegible] [illegible]' [illegible] [illegible] [illegible] [illegible]-[illegible] [illegible] (inhibitory-restoration stack) [illegible] [illegible] [illegible] [illegible] [illegible]
GABRA2 [illegible] [illegible] — [illegible] 30–35%	[illegible] [illegible] [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible] '[illegible] [illegible]
GABRB3 [illegible] [illegible] [illegible]	[illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]	[illegible]/[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]—[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]	[illegible]	[illegible] [illegible] [illegible] [illegible]
		[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

□□□ 3 — □□□□ □□□□□□ □□□□□□□□ □□□ □□□ □□□□

□□□□□ □□□□ □□□□, □□ □□□□ □□□□□ □□□ □□ □□□□□ □□ □□□ □□□□ □□□□ □□□□□□ □□, □□□ □□□□□□□□ □□□□-□□□□ □□□□□ □□ □□□□ □□ □□□□□ □□□□□ □□□ □□□ □□ □□□ □□□□□ □□□ □□ □□□□□ □□□ □□ □□□□□ □□□□ □□□□□□

□□□□□□□□ □□□□□□□□	□□□□□□□□□□□	□□ □□□□□ □□□□□ □□□□□ □□ □□□ □□□□ □□□□□□
□□□□□□□ □□□□□□ — MTHFR T/T + COMT Met/Met	□□□ □□□□□□ + □□□□ □□□□ □□□ □□ □□□□□□□□□	□□□□□□□□□ □□□ □□□□□ □□□ □□□□ □□□ □□□ □□□ □□□ □□□□□ □□□□, □□□□□□/□□□□□□/□□□□ □□□ □□□□ □□□□□□ □□□, □□ □□ □□□□□□□ □□□□: □□□□□□□□□□ 15mg, □□□□□□□□□□ 800mg, SAMe 800mg, □□□□□□, □□□□□ □□□□□□□□
□□□□□□□ □□□□□□□□ □□□□ — MTHFR T/T + COMT Val/Val.	□□□ □□□□□□ + □□□□ □□□□ □□□□□	□□□□□□□□□, □□□□□□, □□□ □□□□□□□□ □□□□□□□□□ □□□□□ □□□ '□□ □□□□□ □□□□□ □□□ □□□□□ □□ □□ □□ □□□□ □□□□□ □□□' □□□□: □□□□□□□□□ 7.5mg, □□□□□□□□, □□□□□□, □□□□□□□□, □□□-□□□□□□□□ □□□□, □□□□□□□□ (Wellbutrin) □□ □□□□□□□□ □□□□□
□□□□□□□□ □□□□□□ — CYP2D6 PM/UM + MTHFR/COMT	□□□ □□□□ □□ □□□□cription + □□□ □□□	□□□ □□□□□□□□□□□□ □□□□ □□□□□□□□□□□□ □□□ '□□ '□□□' □□ □□, □□□ □□□□ □□□-□□□□□□ □□□□□ □□ □□□□ □□□□ □□ □□□□ □□□ □□□□□□ □□□□□□□ □□ □□□□ (□□□□□□□ CYP2D6 □□□ □□□ □□□□ □□)□ □□□: □□□□ □□ □□□ □□□ □□□□□□; Naloxone □□ □□ □□□□
□□□□ □□□□□ □□□□ □□□□ — GABRA2 + COMT Val/Val	□□□□□□ □□□□□□□ + □□□□□ □□ □□□□	□□□□ □□□□□□□ □□□□□□ □□ □□□; □□□□ □□ □□□ □□□ □□□ □□□□ □□□□ □□□ □□□□ □□□ □□□□□ □□□ □□□□: □□□□□ □□□□□□□ □□□□ + □□□□ □□□□□□□□□-□□□□□□□□□ □□□□ + □□□□□□□□□-□□□□□□ □□□□□□□□.
□□□□□-□□-□□□□ □□□□ - GABRA2 + COMT Met/Met	□□□□□□ □□□□ + □□□ □□□-□□□□□□	□□□□ □□□ □□□□ □□ □□□ □□□□ □□ □□□□□ □□□□: □□□ □□□ □□□□ + □□□□□ □□□□ □□□□; □□□□ □□ □□□□ □□□ □□□□□ □□□□ □□ □□□□□ □□ □□□□ □□ □□□□□ □□□□ □□ □□□□ □□□□ □□□□□ □□□
□□□ □□□□-□□□□□□ — GABRA2 + MTHFR T/T	□□□□□□□ □□□□□ □□□ □□□□□□□ □□□□□□	□□□□□ □□□□□ □□□ □□□□ □□□□ □□□□□ □□ □□□ □□: □□□□□□□ □□□□ □□□ □□□□□ □□□ □□□□□ □□□□ □□ □□□-□□□□ □□□□□ □□ □□□□□□□ □□ □□□ □□ □□□ □□□

□□□ □□□□ □□□□ □□□□□□

□□□□□□ □□□□□□ □□□□□□□□ □□□□□□□ □□□□□ □□ □□ □□□□□ □□□□ □□□□ □□: **MTHFR-□□□□□□ →** □□□□□□ □□□□□ □□□□□ **COMT Val/Val →** □□□□□□□□ □□□ □□□□□□ □□□□ □□□

[illegible]	[illegible]	[illegible]
[illegible] **COMT Met/Met →** [illegible] **GABRA2 →** [illegible] **CYP2D6** [illegible]-[illegible] **→** [illegible] **Naloxone** [illegible] **DRD2 A1 →** [illegible] **4-5** [illegible] [illegible]

[illegible] — [illegible]

[illegible]-[illegible]: [illegible]-[illegible], [illegible] '[illegible], [illegible]-[illegible]-[illegible]: [illegible] 2–3 [illegible]

[illegible] A - [illegible] ([illegible])[illegible]

[illegible]: [illegible] 3-4 [illegible] "[illegible]" (Warriors) [illegible] "[illegible]" (Understimulated Warriors) [illegible], [illegible] (stimulant) [illegible]/[illegible] (Withdrawal) [illegible], [illegible], [illegible] "[illegible]" (anhedonia) [illegible]-[illegible]

- **COMT Val/Val** [illegible] **MTHFR T/T** [illegible] **DRD2 A1** [illegible]; [illegible], **GABRA2** [illegible]-[illegible]
- **[illegible]:** [illegible] **—** [illegible], [illegible], [illegible]-[illegible], [illegible]
- **[illegible]/[illegible]:** [illegible]; [illegible] **Wellbutrin,** [illegible]; [illegible]
- **[illegible]:** [illegible] **"[illegible]"** [illegible] **-** [illegible], [illegible], [illegible] '[illegible]

[illegible] [illegible] - [illegible] ([illegible])[illegible]

[illegible]: [illegible] (antagonist) [illegible]/[illegible] (stimulant) [illegible] (depressant) [illegible], [illegible], [illegible] '[illegible]

- **[illegible]:** [illegible] **—** [illegible], [illegible] '[illegible] '[illegible], [illegible]: [illegible], [illegible]
- **[illegible]:** [illegible] **+ COMT** [illegible]; [illegible]/[illegible] **NAC**[illegible] [illegible]-[illegible], [illegible], [illegible]
- **[illegible]:** [illegible], [illegible], [illegible]-[illegible] **—**

□□□□□□□□□□ □□□□□□ □□□□ '□□ □□ □□□□□, □□□□□ □□□□□ □□□□□□□□ □□□□ □□□□ □□□□□ □□□□□ □□□□□ □□□□□□ □□□□

□□□□□ □□□□□□□ □□ - □□□□□□□ (□□□□ □□□□□□-□□□□□□ □□□□□□□□□)□

□□□□□□□□□: 7-□□□□□□□□□□□□□□□□□□□□□□□□□□□ □□□□ □□□□□□ □□□□-□□□□□□ □□□□□□□□ □□□□□□□□ □□□□ □□□□□ □□□□□ □□□□□□-□□□□□ □□□□□□□ □□□□□ □□□□□□ □□—□□ □□□□ □□□□□, □□□□□□ □□□□ '□□ □□□□□□□ □□□□ □□□□□ □□□□□ □□□□□ □□, □□ 12-24 □□□□□□□ □□□□□ □□□□□□ □□□□□□ □□□□ □□ □□□□□ □□□□□□□ □□□□□□ □□□□ □□□□□□□□ □□ □□ "□□□□" □□□□ "□□□□□□□□ □□□□□□□" □□□□□□□ □□□□□□□ '□□ □□, □□□□ □□ □□□□□ □□□□□□□□ □□□□□□ □□□□ □□□□ □□ □□□□□□□ □□□□ □□□□□ □□□□ □□ □□□□□□□ □□□□□□□□ □□ □□□□ □□□□□ □□□□□□

- □□ □□□□□□□□□ □□□□□ □□□□□□□□□□ □□□□□ □□: **COMT Met/Met,** □□□□□ **+ MTHFR T/T; OPRM1** □□□□ **CYP2D6** □□□□□□ □□□□□ □□ □□□□□□ □□□□ □□□□ □□□□□□ □□□□
- □□□□□/□□□□□□ **-** □□ □□ □□□□ □□□□□□□□□□ □□□□ □□: □□□□□□□□□□□□□□□, □□□□□□- □□□□□ □□ □□□□□□□□□ □□ □□□□□□□□ □□□□□ □□, □□□□ □□□□□ □□□□□□□□ □□ □□□□□□ □□, □□□□ □□□□□ □□□□ **ER (□□ □□□□)** □□□□□ □□□□ **MAT (□□□□□□□□□□□-□□□□□□□□ □□□□□□□□□□)** □□□□□□□□□□□□□□□ □□□□ □□□□□ □□ □□□□□ □□□□ □□□□□ **OPRM1** □□-□□□□□ □□, □□□□ □□□□□□□□□□□□ □□ □□□□□ □□□□□ □□□□□□ □□ □□□□ □□□□□□ □□□□□□ □□□□ □□□□ **DLPA** □□□□□□ □□□□ □□□□ **5-10%** □□ □□□□□ □□□□ □□□□□
- □□□□□□□□ □□□□□□-□□□□□□□□□: □□□□ □□□□□□□□□□□ **-** □□□□□□□□□□□□, □□□□□□□□□□□□, **SAMe,** □□□□□□□□, □□□□□ □□□□□□ □□□□□□□ □□□□□ □□ □□□□□□□ □□□□□□□ □□□□ □□; **DLPA** □□□□□□□□□ □□□□□□□ □□ □□□□□ □□□□□□□ □□□□□□□□ □□□□□ **CYP** □□□□□□□□□□□□□□□ □□□□□ □□□□□□□□□□□□ □□□□□□ □□□□ □□□□ □□□□□□□ □□ **-** □□□□ □□ □□□□□□ □□□□ □□□□ □□□□□□□ □□□□□ □□□□□□□ □□□□□□□ □□ □□□□□□□ □□□□□

□□ □□□□□ □□□□ □□□□□□ □□□□□ □□□□□□ □□□□ "□□□□□□ □□□□" □□□□ □□□□□ □□□□□ □□□□□ □□□□□?

□□ □□□□□□ □□□□□□□□ □□ □□□□□ □□□□□ □□□□□□ □□ □□□□ □□□□ □□□□□□ □□□□□□□□□□□□ □□ □□□□□ □□; □□□□□□ □□□□□□□□ □□ □□□□□ □□□□□ □□□□□□ □□ □□□□ '□□ □□□□□□ □□□□ □□□□ □□□□□ □□□□ □□ □□□□ □□ □□□□□□□ □□□□ □□□□ □□, □□ □□□□-□□□□ "□□□□□" **(** □□□□□□□□/□□□□□□□ □□ □□□□□**)** □□□□□□, □□□□□ □□□□ "□□□□□□□" □□ □□□□ □□□□□ "□□□□□□ □□□□□ □□□□□□" □□□□ □□□□ □□□□□□□ □□ □□□□□□ □□□□ □□□□□ □□ □□□□ □□□□□ □□□□□ □□□□□□ □□ □□□□□ □□, □□□□□□ □□□□□ □□□□□ □□□□□ □□ □□□□ □□□□□□ □□, □□ □□□□□ □□□□ □□□□-□□□□ □□□□□□ □□□□ □□□□□ □□□□□□ □□ □□□□ □□ □□□□□ □□□□ □□ □□□□ □□□□□□□ □□□□□□□□□□, □□□□ □□□□□□ **-** □□ □□ □□□□□ □□ □□ □□□□ □□□□□ □□□□□ □□□□□-□□□□□ □□□□□□□ □□ □□□□ □□□□□ □□□□□□□□□

□□□ 5 — □□□□□ □□□□, □□□□ □□□ □□□ □□□□ □□ □□□□□ □□□□□

□□□□□ □□□□ □□□ □□□□□□ □□ □□□□□□ □□□□ □□, □□□□ □□□□ □□ □□□ □□□□□□ □□ □□□□ '□□ □□□□□□□□ □□□□□□□ □□, □□□ □□□□ □□□□ □□□□□□□□ □□ □□□-□□□□□ □□□ □□□□ □□□□□□□ □□ □□□□□□□ □□□□□□□ □□□

□□□□ □□□ - □□□□□□□ □□□□□□ (□□□□□ 1-3)

□□ □□□ □□□ '□□ □□□□ □□□□ □□□□□□□ □□, □□ □□□□□□ □□□□□□□□ □□□□□ □□□□□□ □□□□□ □□□□□ □□□ □□□□□□□□□□ □□ □□□□□ □□□ □□□□ 8 □□□□□□□ □□□□ □□□□-□□□□ □□□□— □□□□ □□ □□□□□ □□□□□ □□□ □□□□ □□□□□ □□, □□□ □□□□ □□□□□ □□□□ □□□□□□ □□□□□□□□□□ □□ □□□□ □□ □□□□ □□ (□□□□□, □□□□□□)□

□□□□□□□□ □□□ (□□□□ □□□□□□□□□□ □□)□

- L-□□□□□□□□□□: 1 □□□□□□□□ □□□ □□□□□ □□□ → 8 □□□□□□□ □□□□ 7.5–15 □□□□□□□□ □□□ (□□□□□ MTHFR □□ □□□□□□□ □□ □□□□ □□)□
- □□□□□□□□□□□□□□□ (□□□□□ B12) 5,000mcg □□□□□□□□□□
  □□□□□□□□□□ □□□□□□□□ 400–800mg□
  P-5-P (B6) 50mg□
  TMG 1,000mg□
- □□□□□-3 (EPA/DHA) 2–3 □□□□□ · NAC 1,200 □□□□□□□□□ (□□ □□□□ □□ □□□□□□□ □□) · □□□□□□□ 1,000 □□□□□□□□□ □□□□□□□ □□□□

□□□□□□ □□-□□ (COMT Val/Val)

- L-□□□□□□□□ 1,000–2,000mg · □□□□□□ □□□□□□□□□ 200–400mg · □□□□□□□□□ 500mg □□□ □□□□ 2 □□□ · □□□□□ □□ □□□□□□□□ 400mg

Sage/Worrier □□-□□ (COMT Met/Met)

- L-□□□□□□ 400mg, □□□ □□□□ 2 □□□ · SAMe 800mg · □□□□□□ 1,000mg · □□□□□□□□ □□□ □□□□ □□□□□□□□□ □□□ □□□□□□ □□□□

□□□□□□□□ □□□□□ □□-□□ (GABRA2/GABRB3 □□□□)□

- □□□□□□□□□□ □□□□□□□□□ 600–800mg, □□□ □□ (□□□□□□□ □□□□□□□□□□□□□)□
  L-□□□□□□□ 400mg, □□□ □□□□ 2 □□□□
  □□□□□□ 1,000mg□
  □□□□□□□ 3g, □□□ □□□ □□□□□□□
  □□ □□: □□□□□□□□□-□□□□□□□ □□□□□□□□ (□□□□)□
  □□□□□ □□ □□□□□□□ □□□ □□□□□□: □□□□□□□□□□/□□□□□□□□□□, □□□□□□□□, KSM-66 □□□□□□□□□□

□□□□ □□□□ — □□□□□ □□□□□□ □□□ □□□□ □□□□□□ (□□□□□ 3-6)□

□□□□ □□□ □□□□□ □□□ □□□□ □□ □□□□□□ □□ □□□□ □□□ □□□□□□□□□ □□□□□ □□□□□□ □□□□□ □□□□ □□ □□□□□ □□□ □□□□ □□ □□□□ □□ □□□□:

- □□□□□□□□/□□□□□□: □□□□□□□□□□□□, □□□ **MAT (□□□□□□□□□-□□□□□□□ □□□□□□□□)** □□□□□□□ □□□; □□ **1-2** □□□□□□□ □□□□ **5-10%** □□ □□□□ □□□□; **DLPA 500mg** □□□ □□□□ **2** □□□; □□□□□□□□□□ □□ □□□□ □□□ □□□.
- □□□□□□□□□□/□□□□□: □□□□□□□□□ □□□□□ **(□□□□□□□□□□□ □□□)**; □□□□□□□□ **2,000mg** □□□, □□□ □□□□ **2** □□□; □□□-□□□□□□ □□□□ □□□□ □□□ □□□□□ □□□□□□□

- **[illegible]/[illegible] ([illegible] [illegible] [illegible] GABRB3-[illegible] [illegible] [illegible]):** [illegible] [illegible] [illegible] [illegible] - [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] **GABA** [illegible] **(**[illegible], [illegible], [illegible], [illegible]**);** [illegible] [illegible]/[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] — [illegible] [illegible] [illegible] ([illegible] 6-12)

[illegible]-[illegible] [illegible] [illegible], [illegible] [illegible]-[illegible] [illegible] [illegible] [illegible] [illegible] (BDNF, D2 [illegible], [illegible] [illegible]) [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible]

	[illegible] (Met/Met)	Sage/Worrier (Met/Met)	GABRA2 ([illegible] [illegible])
[illegible]	HIIT, [illegible], [illegible] [illegible], [illegible]	[illegible], [illegible]-2 [illegible], [illegible], [illegible]	[illegible] [illegible] ([illegible]/[illegible] [illegible] [illegible]), [illegible]-2 [illegible], 4-7-8 [illegible] [illegible]
[illegible] [illegible] [illegible] [illegible] → [illegible] [illegible]	[illegible], [illegible] [illegible] [illegible] [illegible]	HIIT/[illegible] [illegible] → [illegible] [illegible]	[illegible], [illegible] [illegible] [illegible] [illegible]- [illegible], [illegible] [illegible] [illegible] [illegible]
[illegible]	[illegible] [illegible] [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible] '[illegible] [illegible] [illegible] [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible].

[illegible] [illegible] - [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] **('**[illegible] [illegible] [illegible] [illegible]' [illegible]**)**[illegible]

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]: **'2** [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]' **4–8** [illegible] [illegible] [illegible] [illegible]; **'8-**[illegible] [illegible] [illegible]' **12–16** [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] **2–5** [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

□□□ 6 — □□ □□□□ □□□□□□□□ □□□ AI □□□ □□□□□

□□ □□□□□□□ □□□ □□ (AI) □□□□□□□□ □□□□□ □□□□□ □□ □□□□ □□□□ □□□ □□ □□□ □□ □□ □□□□□□ □□ □□□ □□□□□□□□ □□□□□-□□□□□□□ □□□ □□□□ □□□□ □□ □□□— □□□ □□□□ □□ □□□□ □□□□ □□□□ □□□□□ □□□□ □□□□ □□□ □□□□□ □□ □□□□□ □□□□ □□□□□□ □□□□□□□ '□□ □□□□□□ □□□□□ □□□ □□□ □□□ □□□□□□□□ □□□□, □□□ □□□□□ □□□□ □□ □□□□□□-□□□□□□ □□ (AI) □□□□□□ □□ □□□□□□□ □□□□ □□□□ □□ □□□ □□□□□, □□□□ □□ □□□□□ □□; □□ □□□, □□ □□□□□□ □□□□□□□□□□□□, □□□□□□, □□□□□□ □□□ □□□□□□□□ □□□ □□□□ □□□□ □□□□□ □□□

=== □□□□ □□□□□□ □□□□ □□□□□□□□ ===

□□□□□□□ □□□□□□□□□:
MTHFR C677T
MTHFR A1298C
COMT Val158Met (□□□□/□□□□□□□/□□□□)
CYP2D6 (PM/IM/NM/UM)
CYP2C19
GABRA2
GABRB3
OPRM1
DRD2

□□□ □□ □□□□□: □□□□□□□□□□ ___ (□□ □□□□ <10) · □□12 ___ (□□ □□□□ >400) · □□□□□□□ □□ ___ (□□ □□□□ 40–60)

□□□□□ □□□□□ □□ □□□□□□: □□□□ □□□□□(□□) ___ · □□□□□□□□ ___ · □□□□□□ □□□□□ ___ · □□□□□□ □□□□ □□□ □□□□ ___

□□□□□□ □□□□□□: ___

□□□□□□ □□□□□□□□□ (□□□□□ + □□□□): ___

□□□□ □□□□□ □□□□ □□ □□□□: ___

=== □□□□□□□□ □□ □□□ ===

□□□ □□□□□□□ □□ □□□ □□□□ □□□

- □□□□□□□ □□□□□□□□: "□□ □□□□□□ □□ □□□□ '□□, **CPIC/FDA** □□□□□□□□□□□□□ □□□□□□□ □□□□□□ — **[□□□□]** □□ □□□□□□□□ □□□□□□□□□□, □□□□□□□ □□□□□□□□ □□□ □□□□□ □□□□□ □□□□□ □□, □□□□□□ **CYP** □□□□□ □□ □□□□□□□ □□□□□□ □□□ □□□□□□ □□□□ □□□□□□ □□, □□□ □□ □□□ □□□ □□□□□□ □□□□□□□□□ □□□□ □□□□□?"
- □□□□ □□ □□□□□□□ □□□□□□: "□□□□□ **[□□□□]** □□ **[□□□□□]** □□□□□ □□ □□; □□□□ **CYP2D6** □□ □□□□□ **[□□□□□]** □□; □□□□ □□□□□□ □□□□□/□□□□□ □□ □□□□ □□— □□ □□ □□□□ □□□□□ □□□□□□□□ □□ □□□□□ □□? □□ □□□□□ □□□□ □□□□□ □□ □□□ □□? □□ □□ □□□□□ □□□□□ □□□□□ □□ □□□ □□□□□ □□□ □□□□□ □□□□□ □□?"
- □□□□□□□□ □□□□ □□□ □□□□□□ □□□□□□: '□□□□ □□□□ □□□□□□□□, □□□□□□ □□□□, □□□□□□ □□ □□□□□□, □□□□□□□□ □□□ □□ — □□ □□□□□ □□□□ □□□□□□ □□, □□ □□□□□□□□ □□, □□□□ □□□□, □□□□□ □□□□□□, □□□ □□□□ □□□ □□□ □□ □□□ □□□□ □□ □□□ □□□□ □□□□□□?'
- □□□□□□□□ □□□□-□□: '□□ □□□□□ □□ □□□/□□□□/□□□□/□□□□/□□□□ □□ **1–10** □□□□ □□□□□□□□, □□□ □□ □□□□□—□□□□□□□, □□□, □□□□□□□ □□□□□, □□□□ □□□□□ □□ □□□ **priority**□□□?' □□□□□□□ □□□□□□ □□□□□ □□□□ □□□□□□ □□, □□□□ □□□ □□□□□ '□□ □□□□ □□□□ □□□□□ □□□□ □□□□□□□

[illegible]

AI [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]